Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
They make sense conceptually but need clinical trials to determine safety, dosage, timing and interactions
A rat wound healing study showed GHK treatment achieved 64.5% reduction in wound size compared to 45.6% for vehicle-treated and 28.2% for untreated controls
Targeted Delivery & Follicle Signaling: Formulated to optimize the absorption of Caffeine and Niacinamide to invigorate scalp microcirculation while delivering specific bio-signals from GHK-Cu and AHK-Cu
Traditional therapies usually consist of exogenous testosterone administration, which, however, often interferes with natural hormonal regulation
